You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors

Article metrics

Article menu

Download PDFPDF

XML
Research Article
A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: January 2020 to June 2025

AbstractFullPdf
Jan 2020770
Feb 202044440
Mar 202049492
Apr 202035357
May 2020404020
Jun 2020242411
Jul 2020191911
Aug 2020343476
Sep 2020505057
Oct 2020383832
Nov 2020545627
Dec 202011711650
Jan 202112212250
Feb 2021939335
Mar 2021959524
Apr 2021959429
May 2021797814
Jun 202111211235
Jul 2021888823
Aug 2021787813
Sep 202110210122
Oct 202110910941
Nov 202110810838
Dec 2021333319
Jan 2022404315
Feb 2022454632
Mar 2022313021
Apr 2022484925
May 2022333420
Jun 2022232311
Jul 2022323516
Aug 2022545525
Sep 2022272717
Oct 2022363719
Nov 2022404225
Dec 202227279
Jan 2023363618
Feb 2023757611
Mar 2023363715
Apr 2023242419
May 2023222317
Jun 202326264
Jul 2023181820
Aug 2023272713
Sep 202338387
Oct 2023252512
Nov 2023384016
Dec 2023414118
Jan 2024292915
Feb 2024404015
Mar 2024393976
Apr 2024252618
May 2024181814
Jun 2024232312
Jul 2024353516
Aug 2024252510
Sep 2024202018
Oct 2024252512
Nov 2024293017
Dec 2024282811
Jan 2025383823
Feb 202513713714
Mar 2025808015
Apr 2025666716
May 2025363614
Jun 2025303013
Total319032081370